Molecular Diagnostics

British Journal of Cancer (2005) 93, 458–463. doi:10.1038/sj.bjc.6602716 www.bjcancer.com
Published online 2 August 2005

TSPY is a cancer testis antigen expressed in human hepatocellular carcinoma

Y-H Yin1,2, Y-Y Li1,2, H Qiao1,2, H-C Wang1, X-A Yang1, H-G Zhang1, X-W Pang1, Y Zhang1 and W-F Chen1

1Immunology Department, Peking University Health Science Center, Beijing 100083, China

Correspondence: Dr W-F Chen, E-mail: wfchen@public.bta.net.cn

2These authors contributed equally to this work

Received 29 March 2005; Revised 7 June 2005; Accepted 20 June 2005; Published online 2 August 2005.

Top

Abstract

In search for genes associated with hepatocellular carcinoma (HCC) by cDNA microarray, we found that the transcription of TSPY, 'testis-specific protein Y-encoded', was upregulated in HCC. Investigation of a broad spectrum of normal and malignant tissues by RT–PCR revealed the TSPY transcript selectively expressed in normal testis, different histological types of human neoplastic tissues, and tumour cell lines. The expression of TSPY in cancer cells was further confirmed by in situ hybridisation. Indirect immunofluorescence microscopy analysis showed that TSPY was localised mainly in the cytoplasm of transiently transfected cells. Testis-specific protein Y-encoded was detected in 50% (16 of 32) of well- and moderately differentiated HCC patients, in 16% (four of 25) of poorly differentiated HCC patients, and in 5% (one of 19) of renal cell cancer patients. A serological survey revealed that 6.6% (seven of 106) HCC patients had anti-TSPY antibody response, demonstrating the immunogenicity of TSPY in humans. In conclusion, these data suggest that TSPY is a novel cancer/testis (CT) antigen and may be a potential candidate in vaccine strategy for immunotherapy in HCC patients.

Keywords:

testis-specific protein Y-encoded, hepatocellular carcinoma, CT antigen, antibody response, immunotherapy